臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :2826208
	造訪人次 : 31897644 線上人數 : 1289 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"enatsu s"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 1-10 / 12 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-05-02T03:49:13Z	Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY	Nishio M.;Seto T.;Reck M.;Garon E.B.;Chiu C.-H.;Yoh K.;Imamura F.;Park K.;Jin-Yuan Shih;Visseren-Grul C.;Frimodt-Moller B.;Zimmermann A.;Homma G.;Enatsu S.;Nakagawa K.;Relay Study Investigators; Nishio M.; Seto T.; Reck M.; Garon E.B.; Chiu C.-H.; Yoh K.; Imamura F.; Park K.; JIN-YUAN SHIH; Visseren-Grul C.; Frimodt-Moller B.; Zimmermann A.; Homma G.; Enatsu S.; Nakagawa K.; RELAY Study Investigators
臺大學術典藏	2021-04-23T05:56:33Z	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis	Chih-Hsin Yang;Cheng Y.;Murakami H.;Yang P.-C.;He J.;Nakagawa K.;Kang J.H.;Kim J.-H.;Hozak R.R.;Nguyen T.S.;Zhang W.L.;Enatsu S.;Puri T.;Orlando M.; CHIH-HSIN YANG; Cheng Y.; Murakami H.; Yang P.-C.; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M.
臺大學術典藏	2020-12-02T02:33:19Z	Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations	Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Wang X.; Enatsu S.; Puri T.; Orlando M.; Yang J.C.-H.; Cheng Y.; PAN-CHYR YANG et al.
臺大學術典藏	2020-12-02T02:33:06Z	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis	Yang J.C.-H.; PAN-CHYR YANG et al.; Yang J.C.-H.; Cheng Y.; Murakami H.; Pan-Chyr Yang; He J.; Nakagawa K.; Kang J.H.; Kim J.-H.; Hozak R.R.; Nguyen T.S.; Zhang W.L.; Enatsu S.; Puri T.; Orlando M.
臺大學術典藏	2020-08-13T06:33:24Z	The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy	Inoue A.; Omori Y.;Enatsu S.;Brnabic A.J.M.;Rajan N.;Jin-Yuan Shih;Kim J.-H.;Park K.;Inoue A.; Omori Y.; Enatsu S.; Brnabic A.J.M.; Rajan N.; JIN-YUAN SHIH; Kim J.-H.; Park K.
臺大學術典藏	2020-08-13T06:33:24Z	The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy	Inoue A.; Omori Y.;Enatsu S.;Brnabic A.J.M.;Rajan N.;Jin-Yuan Shih;Kim J.-H.;Park K.;Inoue A.; Omori Y.; Enatsu S.; Brnabic A.J.M.; Rajan N.; JIN-YUAN SHIH; Kim J.-H.; Park K.
臺大學術典藏	2020-05-26T09:26:55Z	Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT	Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M.
臺大學術典藏	2020-05-26T09:26:55Z	Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT	Orlando M.;Cheng R;Enatsu S;Barraclough H;Tamura T;Nakagawa K;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M.
臺大學術典藏	2020-05-26T09:26:44Z	Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations	Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:44Z	Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations	Chih-Hsin Yang;Orlando M;Puri T;Enatsu S;Wang X;Kim J.-H;Kang J.H;Nakagawa K;He J;Yang P.-C;Murakami H;Cheng Y; Cheng Y; Murakami H; Yang P.-C; He J; Nakagawa K; Kang J.H; Kim J.-H; Wang X; Enatsu S; Puri T; Orlando M; CHIH-HSIN YANG

顯示項目 1-10 / 12 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目